Wedge Capital Management L L P NC lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 10.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 779,568 shares of the medical equipment provider’s stock after acquiring an additional 73,714 shares during the period. Wedge Capital Management L L P NC’s holdings in Hologic were worth $40,701,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its stake in Hologic by 0.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 42,197,163 shares of the medical equipment provider’s stock valued at $2,026,308,000 after purchasing an additional 116,925 shares during the last quarter. BlackRock Inc. increased its position in shares of Hologic by 0.5% during the 2nd quarter. BlackRock Inc. now owns 18,609,553 shares of the medical equipment provider’s stock valued at $893,630,000 after purchasing an additional 95,737 shares during the last quarter. Parnassus Investments CA raised its stake in shares of Hologic by 1.9% during the 3rd quarter. Parnassus Investments CA now owns 15,825,872 shares of the medical equipment provider’s stock worth $799,048,000 after purchasing an additional 300,090 shares during the period. Nuveen Asset Management LLC raised its stake in shares of Hologic by 72,308.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 5,304,658 shares of the medical equipment provider’s stock worth $254,730,000 after purchasing an additional 5,297,332 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its holdings in shares of Hologic by 17.2% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 1,521,300 shares of the medical equipment provider’s stock worth $73,053,000 after buying an additional 223,217 shares during the last quarter. 94.06% of the stock is owned by institutional investors.
In related news, CEO Stephen P. Macmillan sold 194,396 shares of Hologic stock in a transaction on Monday, November 11th. The shares were sold at an average price of $45.91, for a total value of $8,924,720.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Benjamin Jordan Cohn sold 4,379 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $52.74, for a total transaction of $230,948.46. Insiders sold 251,453 shares of company stock worth $11,871,295 in the last quarter. 0.90% of the stock is currently owned by company insiders.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 EPS for the quarter, hitting the consensus estimate of $0.65. The business had revenue of $865.80 million during the quarter, compared to the consensus estimate of $846.54 million. Hologic had a positive return on equity of 29.67% and a negative net margin of 1.19%. The firm’s revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.58 EPS. On average, sell-side analysts predict that Hologic, Inc. will post 2.62 EPS for the current year.
A number of analysts recently issued reports on the stock. Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $54.00 to $59.00 in a report on Thursday, September 26th. Needham & Company LLC boosted their target price on shares of Hologic from $57.00 to $62.00 and gave the company a “buy” rating in a research note on Monday. Barclays increased their target price on shares of Hologic from $50.00 to $51.00 and gave the company an “equal weight” rating in a research report on Monday. William Blair restated a “buy” rating on shares of Hologic in a research note on Thursday, November 21st. Finally, Citigroup began coverage on shares of Hologic in a report on Monday, January 6th. They issued a “buy” rating and a $60.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $55.38.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: Pattern Day Trader – What is the PDT Rule?
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.